See more : mF International Limited (MFI) Income Statement Analysis – Financial Results
Complete financial analysis of Aclaris Therapeutics, Inc. (ACRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aclaris Therapeutics, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
- Zhongzhu Healthcare Holding Co.,Ltd (600568.SS) Income Statement Analysis – Financial Results
- Bafna Pharmaceuticals Limited (BAFNAPHARM.BO) Income Statement Analysis – Financial Results
- Elmore Limited (ELE.AX) Income Statement Analysis – Financial Results
- BlueRiver Acquisition Corp. (BLUA-WT) Income Statement Analysis – Financial Results
- Ackroo Inc. (AKR.V) Income Statement Analysis – Financial Results
Aclaris Therapeutics, Inc. (ACRS)
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.25M | 29.75M | 6.76M | 6.48M | 4.23M | 10.09M | 1.68M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 18.08M | 11.96M | 4.71M | 5.13M | 4.06M | 6.85M | 1.21M | 120.00K | 90.00K | 0.00 | 0.00 |
| Gross Profit | 13.17M | 17.79M | 2.05M | 1.35M | 172.00K | 3.24M | 476.00K | -120.00K | -90.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 42.14% | 59.80% | 30.29% | 20.81% | 4.07% | 32.12% | 28.28% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 98.38M | 77.81M | 43.81M | 31.73M | 64.90M | 63.01M | 39.79M | 33.48M | 15.34M | 6.51M | 3.49M |
| General & Administrative | 31.10M | 25.13M | 23.62M | 20.53M | 27.16M | 27.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 283.00K | 671.00K | 48.00M | 85.00K | 3.30M | 0.00 | 0.00 | 0.00 |
| SG&A | 31.10M | 25.13M | 23.62M | 20.53M | 27.83M | 75.65M | 33.11M | 15.09M | 5.33M | 2.03M | 1.77M |
| Other Expenses | 0.00 | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | 2.07M | 488.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 130.80M | 102.95M | 67.43M | 52.26M | 92.73M | 138.66M | 72.90M | 48.57M | 20.67M | 8.53M | 5.26M |
| Cost & Expenses | 128.61M | 114.91M | 72.15M | 57.39M | 96.78M | 145.51M | 74.11M | 48.57M | 20.67M | 8.53M | 5.26M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 104.00K | 16.00K | 21.00K |
| Interest Expense | 0.00 | 4.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 863.00K | 797.00K | 923.00K | 1.32M | 1.59M | 1.32M | 402.00K | 120.00K | 90.00K | 12.00K | 11.00K |
| EBITDA | -117.57M | -84.36M | -65.06M | -48.20M | -90.84M | -80.78M | -53.45M | -48.57M | -20.67M | -8.52M | -5.25M |
| EBITDA Ratio | -376.22% | -267.74% | -607.08% | -785.44% | -1,751.83% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -97.36M | -85.15M | -65.38M | -50.91M | -111.06M | -135.41M | -72.42M | -48.57M | -20.67M | -8.53M | -5.26M |
| Operating Income Ratio | -311.55% | -286.21% | -967.08% | -785.44% | -2,627.35% | -1,341.93% | -4,303.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 8.51M | 2.95M | -1.14M | -424.00K | -2.48M | 2.68M | -15.99M | 488.00K | 104.00K | 16.00K | 21.00K |
| Income Before Tax | -88.85M | -86.91M | -90.87M | -51.34M | -113.54M | -132.74M | -70.35M | -48.08M | -20.56M | -8.52M | -5.24M |
| Income Before Tax Ratio | -284.32% | -292.11% | -1,343.96% | -791.98% | -2,686.11% | -1,315.41% | -4,180.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -367.00K | 1.75M | 23.42M | -182.00K | 29.31M | 2.68M | -1.83M | -120.00K | -90.00K | 0.00 | 0.00 |
| Net Income | -88.48M | -88.66M | -114.28M | -51.15M | -142.85M | -132.74M | -68.52M | -48.08M | -20.56M | -8.52M | -5.24M |
| Net Income Ratio | -283.15% | -298.00% | -1,690.30% | -789.17% | -3,379.47% | -1,315.41% | -4,071.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| EPS Diluted | -1.27 | -1.36 | -2.01 | -1.20 | -3.46 | -4.03 | -2.44 | -2.25 | -3.37 | -0.80 | -0.49 |
| Weighted Avg Shares Out | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
| Weighted Avg Shares Out (Dil) | 69.81M | 65.21M | 56.73M | 42.54M | 41.32M | 32.91M | 28.10M | 21.42M | 6.11M | 10.66M | 10.66M |
Aclaris (ACRS) Stock Rises on Appointment of New Interim CEO
Aclaris (ACRS) Down 21% on Mixed Results From Eczema Study
Aclaris Therapeutics shares torpedo on underwhelming dermatitis trial results
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Aclaris Therapeutics Provides Corporate Update
Best Penny Stocks To Buy? 4 To Watch With Big News This Week
Penny Stocks To Buy Now? 5 Under $5 To Watch This Week
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Source: https://incomestatements.info
Category: Stock Reports